FDA Approves CARVEDILOL — Advagen Pharma Limited
Advagen Pharma Limited announced on Tuesday the approval of its Abbreviated New Drug Application (ANDA 078786) to manufacture and market carvedilol oral tablets, a blockbuster beta-blocker therapy. This approval enables the company to immediately compete in the cardiovascular market, potentially increasing generic availability and driving significant price competition against originator brands.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed